CD27 synergizes with CD40 to induce IgM, IgG, and IgA antibody responses of peripheral blood B cells in the presence of IL-2 and IL-10 - PubMed

CD27 synergizes with CD40 to induce IgM, IgG, and IgA antibody responses of peripheral blood B cells in the presence of IL-2 and IL-10

Testuo Hirano et al. Immunol Lett. 2003.

Abstract

CD40, a member of the tumor necrosis factor receptor (TNFR) family, promotes IgM, IgG, and IgA antibody (Ab) synthesis in combination with a variety of cytokines. Another TNFR family member, CD27, causes B cells to differentiate into antibody-forming cells, with marginal effects on proliferation. In the present study, we examined whether anti-CD27 monoclonal antibody (mAb) modulates the antibody production induced by anti-CD40 mAb immobilized on L cells expressing FcgammaRII (CDw32) in the presence of IL-2 and/or IL-10. The anti-CD40 mAb substantially enhanced IgM, IgG, and IgA production in combination with IL-2 and IL-10, whereas anti-CD27 mAb augmented it only marginally, as assessed by enzyme-linked immunosorbent assay. The addition of anti-CD27 mAb enhanced the anti-CD40-mediated IgM, IgG, and IgA antibody production only when both IL-2 and IL-10 were present in the culture. The CD27-positive B cell compartment generated synergistic antibody responses in response to four different stimulants, anti-CD27/anti-CD40 mAb and cytokines IL-2/IL-10, whereas the CD27-negative B cell compartment failed to do so. Kinetic analysis showed that anti-CD40 might function in the early phase of B cell activation, while anti-CD27 mAb functioned in the late stage. The addition of CD27(-) to CD27(+) B cells in various ratios did not have any effect on the antibody production, suggesting that CD27(+) to CD27(-) B cell interaction does not occur in this system. Our findings suggest that a member of the TNFR family, CD27, cooperates with CD40 to induce efficient antibody production in combination with cytokines IL-2 and IL-10.

Similar articles

• Synergistic augmentative effect of interleukin-10 and CD27/CD70 interactions on B-cell immunoglobulin synthesis.

  Nagumo H, Agematsu K. Nagumo H, et al. Immunology. 1998 Jul;94(3):388-94. doi: 10.1046/j.1365-2567.1998.00521.x. Immunology. 1998. PMID: 9767422 Free PMC article.

• The different process of class switching and somatic hypermutation; a novel analysis by CD27(-) naive B cells.

  Nagumo H, Agematsu K, Kobayashi N, Shinozaki K, Hokibara S, Nagase H, Takamoto M, Yasui K, Sugane K, Komiyama A. Nagumo H, et al. Blood. 2002 Jan 15;99(2):567-75. doi: 10.1182/blood.v99.2.567. Blood. 2002. PMID: 11781240

• CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses.

  Morimoto S, Kanno Y, Tanaka Y, Tokano Y, Hashimoto H, Jacquot S, Morimoto C, Schlossman SF, Yagita H, Okumura K, Kobata T. Morimoto S, et al. J Immunol. 2000 Apr 15;164(8):4097-104. doi: 10.4049/jimmunol.164.8.4097. J Immunol. 2000. PMID: 10754303

• Plasma cell generation from B-lymphocytes via CD27/CD70 interaction.

  Agematsu K, Hokibara S, Nagumo H, Shinozaki K, Yamada S, Komiyama A. Agematsu K, et al. Leuk Lymphoma. 1999 Oct;35(3-4):219-25. doi: 10.3109/10428199909145724. Leuk Lymphoma. 1999. PMID: 10706444 Review.

• The CD40 antigen and its ligand.

  Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. Banchereau J, et al. Annu Rev Immunol. 1994;12:881-922. doi: 10.1146/annurev.iy.12.040194.004313. Annu Rev Immunol. 1994. PMID: 7516669 Review.

Cited by

• Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

  Iuchi T, Teitz-Tennenbaum S, Huang J, Redman BG, Hughes SD, Li M, Jiang G, Chang AE, Li Q. Iuchi T, et al. Cancer Res. 2008 Jun 1;68(11):4431-41. doi: 10.1158/0008-5472.CAN-07-5530. Cancer Res. 2008. PMID: 18519706 Free PMC article.

• Modulation of human immune responses by bovine interleukin-10.

  den Hartog G, Savelkoul HF, Schoemaker R, Tijhaar E, Westphal AH, de Ruiter T, van de Weg-Schrijver E, van Neerven RJ. den Hartog G, et al. PLoS One. 2011 Mar 25;6(3):e18188. doi: 10.1371/journal.pone.0018188. PLoS One. 2011. PMID: 21464967 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal